熱門資訊> 正文
Elicio Therapeutics发布了自然医学1期AMPLUTE-201研究的后续数据
2025-08-12 20:11
- At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months
- Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS") induced by ELI-002
- 77% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacy
- ELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in most patients, and evidence of antigen-spreading to patient-specific neoantigens not included in ELI-002 was observed
- Final event-driven disease-free survival ("DFS") analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P monotherapy in pancreatic ductal adenocarcinoma ("PDAC") is anticipated in Q4 2025
- Final event-driven disease-free survival ("DFS") analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P monotherapy in pancreatic ductal adenocarcinoma ("PDAC") is anticipated in Q4 2025
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
